HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China

HUTCHMED has announced that its SANOVO clinical trial demonstrated a significant improvement in progression-free survival for patients with MET-overexpressing EGFR-mutated non-small cell lung cancer (NSCLC) treated with a combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib). The results, based on data from the trial in China, mark a notable development in targeted lung cancer therapies and could influence treatment strategies in the region.

The SANOVO trial, conducted by HUTCHMED, evaluated the efficacy of combining ORPATHYS® (savolitinib), a MET inhibitor, with TAGRISSO® (osimertinib), an EGFR TKI, in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC. According to HUTCHMED, the trial results showed a statistically significant extension in progression-free survival (PFS) compared to historical controls or other standard treatments, although specific numerical data has not yet been disclosed.

HUTCHMED emphasized that the trial’s findings suggest the combination therapy could offer a new treatment option for a subset of lung cancer patients who have limited options due to MET overexpression and EGFR mutations. The company stated that these results are preliminary and further detailed data will be presented at upcoming medical conferences.

It is important to note that the trial was conducted exclusively in China, where the patient population and healthcare landscape differ from other regions. The company also clarified that the results are based on interim analysis, and the final outcomes are pending further follow-up and validation.

Potential Impact on Lung Cancer Treatment Strategies

The reported progress in the SANOVO trial could have significant implications for the treatment of EGFR-mutated NSCLC with MET overexpression, a subgroup often associated with resistance to standard therapies. If confirmed in larger, phase III studies, the combination of ORPATHYS® and TAGRISSO® might become a new standard of care in China and potentially influence treatment approaches elsewhere.

This development is especially relevant given the rising interest in targeted therapies that address specific genetic mutations and overexpressions in lung cancer. The promising results could also bolster HUTCHMED’s position in the oncology market, as the company advances its pipeline of targeted treatments.

However, it remains uncertain how these findings will translate into broader clinical practice, and whether similar benefits will be observed in diverse patient populations outside China. Regulatory approval processes and further validation are still needed before the therapy can be widely adopted.

Background on Targeted Therapies for EGFR and MET in Lung Cancer

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, with EGFR mutations being a common driver in many cases. Targeted therapies like TAGRISSO® have transformed treatment for EGFR-mutated NSCLC, but resistance often develops, sometimes involving MET overexpression or amplification.

HUTCHMED’s development of ORPATHYS® (savolitinib), a MET inhibitor, aims to address this resistance mechanism. Combining MET inhibitors with EGFR-targeted therapies has been a focus of recent research, with several early-phase trials exploring their synergistic potential.

The SANOVO trial builds on this context, aiming to evaluate whether this combination can improve outcomes in a specific genetic subset of lung cancer patients. Prior studies have shown mixed results, and this trial’s promising interim data has attracted attention in the oncology research community.

Pending Data and Broader Validation of Results

It is not yet clear whether the trial’s interim results will be confirmed in larger, phase III studies. The detailed numerical data, including median PFS and statistical significance levels, have not been publicly disclosed. Additionally, the trial’s results are based on an interim analysis, and final outcomes could differ after longer follow-up.

Further, it remains uncertain how these findings will influence regulatory approvals and clinical practice outside China. The generalizability of the results to diverse populations and healthcare systems is still to be determined.

Next Steps Include Further Data Analysis and Regulatory Review

HUTCHMED plans to present comprehensive data from the SANOVO trial at upcoming medical conferences, which will include detailed efficacy and safety results. The company also intends to initiate or participate in larger, confirmatory phase III trials to validate these findings.

Regulatory agencies in China and possibly other regions will review the full data set for approval considerations. If the results are confirmed, the combination therapy could be submitted for regulatory approval within the next year or two.

Meanwhile, researchers and clinicians will monitor additional trial outcomes, including overall survival and quality of life measures, to determine the therapy’s full clinical value.

Key Questions

What is the SANOVO trial testing?

The SANOVO trial is evaluating the efficacy of combining ORPATHYS® (savolitinib), a MET inhibitor, with TAGRISSO® (osimertinib), an EGFR TKI, in treatment-naïve patients with MET-overexpressing EGFR-mutated non-small cell lung cancer in China.

What are the main findings announced?

HUTCHMED announced that the trial demonstrated a significant progression-free survival benefit for the combination therapy based on interim analysis, though specific data has not yet been disclosed.

Why is this development important?

If confirmed, these results could lead to new treatment options for a difficult-to-treat subgroup of lung cancer patients and impact future clinical practice and drug approvals in China and beyond.

What are the next steps for this research?

HUTCHMED plans to present detailed data at upcoming conferences and pursue larger, phase III trials to validate the findings, with potential regulatory submissions following positive results.

Are these results applicable outside China?

It is currently unclear whether the findings will be replicated in diverse populations outside China, and further studies are needed to confirm generalizability.

Source: primary